Raviraj Jayam, Bokkasam Vijay Kumar, Kumar Venkata Suneel, Reddy Uday Shankar, Suman Venkata
Department of Oral Medicine and Radiology, CKS Theja Dental College, Hospital and Research Centre, Tirupati, Andhra Pradesh, India.
Indian J Dent Res. 2014 Jan-Feb;25(1):83-90. doi: 10.4103/0970-9290.131142.
Radiotherapy is regarded as one of the most important therapeutic modality for the treatment of malignant lesions. This field is undergoing rapid advancements in the recent times. With the use of radiosensitizers and radioprotective agents, the course of radiotherapy has improved the sensitization of tumor cells and protection of normal cells, respectively. The aim of this paper was to critically review and analyze the available compounds used as radiosensitizers, radioprotectors, and radiation mitigators. For reviewing, the author used the electronic search for the keywords 'Radiosensitizers', 'Radioprotectors', 'Radiation mitigators' on PubMed for inclusion of previously published articles and further search of reference papers on individual radiosensitizing and radioprotecting agents was done. Radiosensitizers are agents that sensitize the tumor cells to radiation. These compounds apparently promote fixation of the free radicals produced by radiation damage at the molecular level. The mechanism of action is similar to the oxygen effect, in which biochemical reactions in the damaged molecules prevent repair of the cellular radiation damage. Free radicals such as OH + are captured by the electron affinity of the radiosensitizers, rendering the molecules incapable of repair. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present before or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. This article tries to discuss the various aspects of radiosensitizers, radioprotectors, and radiation mitigators including the newer agents.
放射治疗被视为治疗恶性病变最重要的治疗方式之一。近年来,该领域正在迅速发展。通过使用放射增敏剂和辐射防护剂,放射治疗过程分别提高了肿瘤细胞的敏感性和对正常细胞的保护作用。本文的目的是批判性地综述和分析用作放射增敏剂、辐射防护剂和辐射减轻剂的现有化合物。为了进行综述,作者在PubMed上通过电子搜索关键词“放射增敏剂”“辐射防护剂”“辐射减轻剂”来纳入先前发表的文章,并进一步搜索了关于个别放射增敏剂和辐射防护剂的参考文献。放射增敏剂是使肿瘤细胞对辐射敏感的药物。这些化合物显然在分子水平上促进了辐射损伤产生的自由基的固定。其作用机制类似于氧效应,即受损分子中的生化反应阻止细胞辐射损伤的修复。诸如OH+等自由基被放射增敏剂的电子亲和力捕获,使分子无法修复。辐射防护剂是旨在减少辐射对正常组织造成损伤的化合物。这些化合物通常是抗氧化剂,必须在辐射前或辐射时存在才能发挥作用。其他被称为减轻剂的药物,即使在已经进行辐射后也可用于将毒性降至最低。本文试图讨论放射增敏剂、辐射防护剂和辐射减轻剂的各个方面,包括新型药物。
Indian J Dent Res. 2014
Clin Transl Oncol. 2018-8-22
Eur J Pharmacol. 2017-12-6
Int J Radiat Biol. 2019-12-2
Int J Nanomedicine. 2021
Nihon Igaku Hoshasen Gakkai Zasshi. 1986-5-25
Mol Med Rep. 2023-3
Rev Fr Etud Clin Biol. 1964-4
IET Nanobiotechnol. 2024
Biology (Basel). 2022-8-9
J Nanobiotechnology. 2022-3-5
Burns Trauma. 2022-1-21